Kirby McInerney LLP has launched an investigation into Alnylam Pharmaceuticals over potential securities law violations. The probe follows Alnylam's July 30, 2026 announcement of second quarter results, in which it lowered full-year 2026 TTR product sales guidance by approximately $200 million, citing normalization of second-line volume growth after initial pent-up demand in the ATTR-CM market. On that news, Alnylam shares fell $81.14, or about 28%, to close at $205.48. No lawsuit has been filed, and the investigation is ongoing. The law firm is inviting investors who purchased Alnylam securities to contact them for more information.
Alnylam Pharmaceuticals IncCompany lowered full-year guidance and shares fell 28% on the news, prompting a securities fraud investigation.